SPONSORED

Dutch government fails at allowing cannabis cultivation

The government of the small European country have committed some grave errors in the process.

•• 3 Min
Dutch government fails at allowing cannabis cultivation

It's never easy to be green. However, the cannabis industry is no stranger to overcoming stigmas, if not hurdles. Not to mention the grotesque loses of the ball once governments intervene - from expanding access to basic regulation. The Dutch government has just received a reminder as their widely lauded first grow offer for the production of regulated recreational cannabis has been embarrassingly skidded. It's not even something to blame for COVID-19. Nor does it look like the Dutch have drawn any lessons from the highly controversial German cannabis tender for medicinal cultivation in 2017, which has not yet gone fully online. Holland is a sovereign country with 2 million fewer people than the US state of New York. What's going on there? How could the country of the coffee shop waste the ball so badly? At least for American Generation X, Holland became a beacon of cannasanity in the 1980s and 1990s. It was a time when American baby boomers in particular, who had inhaled with impunity in their vaunted youth, decided to further criminalize the plant and those who grew, used or sold it as they gained positions of political power. Drug testing became a bane for anyone trying to work in the United States. In Europe, things were better, but only just barely. One can still be arrested for possession, use, or sale of the drug. Just ask Spanish club owners during COVID-19. But drug testing never caught on, and neither did the obscene extremes of the drug war in the United States. As a result, there's a highly profitable, if not widespread, "underground" if you can call it that - from the mafia and terror-affiliated groups to entrepreneurial-minded patients with grow room and a few friends. Far beyond Holland, for example, there are many German magazines, if not an entire subculture based on home growing, which has certainly begun to organize for bigger things in recent years as medical use has become legal here. And if you really wanted to smoke weed in public, you could always take a visa-free trip across one border or another if you didn't have friends and didn't want to "shop" in the main station area of ​​your local city. At least in Germany, you can find regulated sex trafficking and of course plenty of opportunities to buy all kinds of illegal substances. The situation was not hidden from the Dutch authorities. Indeed, various unsuccessful attempts have been made to curb the popularity of cannatourism and all have failed. These ranged from trying to shut down industry in border towns (especially with Germany) to introducing stricter regulations in the places where industry was active. See Amsterdam from yesterday and January 2021. None of these attempts during the first decade and a half of the twenty-first century, although they caused losses, both legitimate and unjustified. For example, by 2014, coffee shops in every city that were located in the immediate vicinity of schools were closed due to such measures. There are around half as many shops in Amsterdam today as there were at the turn of the century. The other (international) victim was the famous Cannabis Cup competition. However, this did not solve the bigger problems. The coffeeshops that were still in operation had to find products somewhere - and while their storefronts may have dwindled, sales rose, and not just because other coffeeshops were closed. There was suddenly an upswing among local users. Until 2017, there was also a healthy domestic medical market, isolated from the coffee shop trade, because Dutch insurers were still reimbursing cannabis prescriptions from local patients. The fact that this ended when the German insurance industry was forced to cover medical cannabis claims meant that Dutch patients were then also forced into coffee shops just under four years ago. Indeed, from now on the formally medically regulated Dutch medical industry is mainly oriented towards export. If it weren't for Bedrocan, the oldest private grower in the world, the repeated mistakes in the German range would have eliminated most of the medical Flos that are still in pharmacies today.

The NetherlandsCannabislegalization

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.